Eli Lilly Unveils Promising Alzheimer's Advances

Eli Lilly is set to showcase new research on Alzheimer's disease at the AAIC 2026 conference, particularly focusing on diagnostic blood tests and treatment options. They're introducing new data on the P-tau217 blood test and amyloid-targeting treatments, which could make diagnosing and treating Alzheimer's more accessible and effective. The presentations include long-term insights into their drug Kisunla and its impact on Alzheimer's progression. What does it mean for you? If you're concerned about Alzheimer's, this research could mean more accurate and accessible diagnostics in the future, potentially leading to earlier detection and better treatment options.